Biotech Values

[genisi]

The Novo Nordisk work from 2000 determined mitogenic potencies of insulin analogs only in one cancerous cell type - human osteosarcoma cells. I am aware of at least one other, more recent work, of independent scientists (Weinstein et. al., 2009) that looked at several cell lines. See abstract and results which are summarized in the table below.

http://www.ncbi.nlm.nih.gov/pubmed/19145584



So the question may be: are some insulin analogues more stimulatory for cancer behavior (in already transformed cells).